Denosumab increases bone density, cuts fracture risk in prostate cancer survivors
Tuesday, August 11, 2009 - 10:42
in Health & Medicine
Twice-yearly treatment with denosumab, a new targeted therapy to stop bone loss, increased bone density and prevented spinal fractures in men receiving androgen-deprivation therapy for prostate cancer.